OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cohen on the Quality of Life in Head and Neck Cancer

November 7th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the unmet need facing the quality of life for patients with head and neck cancer.

Dr. Mikhail on Ongoing Clinical Trials for Patients With Myeloma

November 7th 2017

Sameh Mikhail, MD, medical oncologist, The Mark H. Zangmeister Cancer Center, discusses ongoing clinical trials for patients with myeloma.

Dr. West on FDA Approval of Frontline Alectinib in ALK+ NSCLC

November 7th 2017

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of alectinib (Alecensa) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

Dr. Rugo on Hormone Therapy for Patients With Breast Cancer

November 7th 2017

Hope S. Rugo MD, professor of medicine and director of breast oncology and clinical trials education, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses hormone therapy for patients with breast cancer.

Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC

November 3rd 2017

Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).

Dr. Blumenschein on Immunotherapy Combinations in NSCLC

November 3rd 2017

George R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).

Dr. Lam Discusses Agents for ROS1-Mutated NSCLC

November 3rd 2017

Vincent Lam, MD, assistant professor, The University of Texas MD Anderson Cancer, discusses agents to target ROS1-mutated non-small cell lung cancer (NSCLC).

Dr. Bouvet on Remaining Challenges With Thyroid Cancer Surgery

November 3rd 2017

Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses the remaining challenges with thyroid cancer surgery.

Dr. Sacco on Upfront Treatments for Head and Neck Cancer

November 3rd 2017

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses upfront treatment for patients with head and neck cancer.

Dr. Maloney on Future Treatment With CAR T-Cell Therapy

November 3rd 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the future treatment landscape for chimeric antigen receptor (CAR) T-cell therapy.

Dr. Califano on the Future of Surgery in Head and Neck Cancer

November 3rd 2017

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the future of surgery in head and neck cancer.

Dr. Stadtmauer on Current Challenges With Multiple Myeloma

November 3rd 2017

Dr. Perl on the Outlook of FLT3 Inhibitors for AML

November 3rd 2017

Alexander E. Perl, MD, associate professor of medicine, University of Pennsylvania, discusses the outlook of FLT3 inhibitors for acute myeloid leukemia.

Dr. Epperla on Treatment Following Ibrutinib in MCL

November 1st 2017

Narendranath Epperla, MBBS, MS, hematologist, The Ohio State University (OSU) Comprehensive Cancer Center, assistant professor in internal medicine, OSU, discusses the next steps for patients with mantle cell lymphoma (MCL) who fail ibrutinib (Imbruvica).

Dr. Aggarwal on the Future of ADT for Patients With Prostate Cancer

November 1st 2017

Rahul Aggarwal, MD, an assistant professor of Hematology/Oncology, director of the STAND Clinic, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses the future of androgen deprivation therapy (ADT) for patients with prostate cancer.

Dr. Maloney Discusses CAR T-Cell Therapy in Solid Tumors

November 1st 2017

David G. Maloney, MD, PhD, member of the Clinical Research Division, Fred Hutchinson Cancer Research Center in Seattle, Washington, discusses using CAR T-cell therapy in solid tumors.

Dr. Armstrong Discusses Hereditary Prostate Cancer

November 1st 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

Dr. Camidge Discusses Unmet Needs in ALK+ Lung Cancer

November 1st 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses unmet needs for patients with ALK-positive lung cancer.

Dr. Ryan on Bone-Targeting Agents for Patients With Prostate Cancer

November 1st 2017

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Dr. Geynisman on Patient Preferences for Treatment of RCC

November 1st 2017

Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses patient preferences for the treatment of renal cell carcinoma (RCC).